The invention encompasses novel compounds of Formula I ##STR00001## or
pharmaceutically acceptable salts thereof. These compounds are inhibitors
of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are
therefore useful to treat pain and/or inflammation from a variety of
diseases or conditions, such as osteoarthritis, rheumatoid arthritis and
acute or chronic pain. Methods of treating diseases or conditions
mediated by the mPGES-1 enzyme and pharmaceutical compositions are also
encompassed.